REGENXBIO Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 28.91 million compared to USD 26.51 million a year ago. Net loss was USD 61.87 million compared to USD 75.48 million a year ago. Basic loss per share from continuing operations was USD 1.41 compared to USD 1.75 a year ago.
For the nine months, revenue was USD 68.03 million compared to USD 81.38 million a year ago. Net loss was USD 200.61 million compared to USD 220.39 million a year ago. Basic loss per share from continuing operations was USD 4.6 compared to USD 5.11 a year ago.